AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.
Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales
by Zacks Equity Research
Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.
Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Bayer (BAYRY) exceeds earnings estimates in the first quarter of 2019 and sales rise year over year.
What's in the Cards for AstraZeneca (AZN) in Q1 Earnings?
by Zacks Equity Research
AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.
AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.
Top Ranked Income Stocks to Buy for April 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 17th
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
by Zacks Equity Research
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
by Kinjel Shah
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall
by Swarup Gupta
The index traversed a lackluster trading week as investors looked toward first-quarter earnings numbers for direction.
Alkermes Reports Positive Data From Schizophrenia Study
by Zacks Equity Research
Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) sales growth in first-quarter 2019 is expected to be hurt by generic/biosimilar headwinds in the Pharma unit.
AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
PhaseBio Stock Up on Breakthrough Therapy Status for PB2452
by Zacks Equity Research
FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.
Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457
by Zacks Equity Research
Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
by Kinjel Shah
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
by Kinjel Shah
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Will Ironwood Suffer From Dependence on Linzess' Progress?
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
by Kinjel Shah
Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck
by Zacks Equity Research
The expanded partnership will help Myriad Genetics (MYGN) boost top-line contributions in the near term.
Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up
by Zacks Equity Research
Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.
Clovis Posts Data on Rubraca Study for Pancreatic Cancer
by Zacks Equity Research
Clovis (CLVS) presents interim data from the phase II study on Rubraca for the first-line maintenance treatment of patients with advanced pancreatic cancer.
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
Advaxis Up on Positive Early-Stage Immunotherapy Study Data
by Zacks Equity Research
Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.
AstraZeneca's Selumetinib Gets Breakthrough Therapy Status
by Zacks Equity Research
AstraZeneca's (AZN) MEK 1/2 inhibitor, selumetinib gets Breakthrough Therapy designation for the treatment of paediatric patients with inoperable NF1-related PN.